WAYNE STATE UNIVERSITY Patent applications |
Patent application number | Title | Published |
20160074401 | COMPOSITIONS AND METHODS UTILIZING PHOSPHODIESTERASE INHIBITORS TO TREAT BLAST-INDUCED TINNITUS AND/OR HEARING LOSS - The present disclosure provides compositions and methods utilizing phosphodiesterase inhibitors to treat blast-induced tinnitus and/or hearing loss. The compositions include phosphodiesterase inhibitors such as sildenafil. | 03-17-2016 |
20160040216 | SYSTEMS AND METHODS TO ASSES MICROBIOMES AND TREATMENTS THEREOF - Systems and methods to assess the health of various microbiomes and to identity species therein are disclosed. Described assessments and identifications can inform treatment decisions if a microbiome is determined to have a less than optimal balance of bacterial species within it; the presence of one or more negative species; and/or the absence of one or more positive species. | 02-11-2016 |
20150377889 | GALECTIN-3 AS A MARKER FOR PROSTATE CANCER - Provided are methods and kits for the use of galectin-3, alone or in combination with prostate specific antigen (PSA), as a marker for the presence or absence of and/or activity of prostate cancer. | 12-31-2015 |
20150355183 | NEOEPITOPE DETECTION OF DISEASE USING PROTEIN ARRAYS - A biosensor for use in detecting the presence of diseases, the biosensor comprising a detector for detecting a presence of at least one marker indicative of a specific disease. A method of determining efficacy of a pharmaceutical for treating a disease or staging disease by administering a pharmaceutical to a sample containing markers for a disease, detecting the amount of at least one marker of the disease in the sample, and analyzing the amount of the marker in the sample, whereby the amount of marker correlates to pharmaceutical efficacy or disease stage. Markers for gynecological disease. An immuno-imaging agent comprising labeled antibodies, whereby the labeled antibodies are isolated and reactive to proteins overexpressed in vivo. Informatics software for analyzing the arrays, the software including analyzing means for analyzing the arrays. | 12-10-2015 |
20150307937 | ACTIVITY-DEPENDENT GENE PAIRS AS THERAPEUTIC TARGETS AND METHODS AND DEVICES TO IDENTIFY THE SAME - Activity-dependent gene pairs as therapeutic targets and methods and devices to identify the same are provided. The methods and devices allow transcriptome-wide analysis of regulatory long non-coding RNAs (IncRNAs), matched with differentially expressed protein-coding genes (mRNAs) and/or with other IncRNAs. The described methods and devices allow analysis of these activity-dependent gene pairs as therapeutic targets in a number of clinical conditions associated with altered electrical brain activity, including epilepsy. | 10-29-2015 |
20150300278 | USING ION CURRENT SIGNAL FOR ENGINE PERFORMANCE AND EMISSIONS MEASURING TECHNIQUES AND METHOD FOR DOING THE SAME - A system and method is provided for the use of the ion current signal characteristics for onboard cycle-by-cycle, cylinder-by-cylinder measurement. The system may also control the engine operating parameters based on a predicted NOx emission level, CO emission level, CO | 10-22-2015 |
20150299180 | NEUROPROTECTIVE AGENTS FOR TREATMENT OF NEURODEGENERATIVE DISEASES - A compound having formula I is useful for treating a neurodegenerative disease: | 10-22-2015 |
20150126536 | Methods of Using Selective Chemotherapeutic Agents for Targeting Tumor Cells - A method for treating cancer tumors, particularly ovarian cancer tumors, is described, where fused cyclic pyrimidine having a cancer treating ability is selectively delivered to an FR expressing cancerous tumor. | 05-07-2015 |
20150053854 | SYSTEMS AND METHODS EXTENDING THE LASERSPRAY IONIZATION MASS SPECTROMETRY CONCEPT FROM ATMOSPHERIC PRESSURE TO VACUUM - Disclosed herein are systems and methods that allow analysis of macromolecular structures using laserspray ionization at intermediate pressure or high vacuum using commercially available mass spectrometers with or without modification and with the application of heat. The systems and methods produce multiply-charged ions for improved analysis in mass spectrometry. | 02-26-2015 |
20150038751 | BIMETAL CATALYSTS - The present disclosure discloses bimetal catalysts. | 02-05-2015 |
20150038378 | BIOCOMPATIBLE GRAPHENE SENSOR - A graphene biosensor is formed on an electrically insulating substrate with a single-layer graphene sheet arranged between two metallic electrodes. The graphene sheet is in electrical contact with the metallic electrodes. The graphene sheet has perforations creating edges in the graphene sheet. The perforations may be holes on a micrometer scale or in a nanometer scale. The biosensor can be configured as an ISFET. The graphene sheet may comprise affinity probes immobilized on the edges for attaching specific molecules to the graphene sheet. Several graphene sheets may be arranged in a microarray with different affinity probes on different graphene sheets. The sensor may also be arranged on the distal end of a catheter for in situ measurements in a body vessel. | 02-05-2015 |
20150029504 | FOURIER-TRANSFORM INTERFEROMETER WITH STAIRCASE REFLECTIVE ELEMENT - An apparatus for performing Raman spectral analysis of a sample is described, comprising a coherent light source, an first optical chain to direct the coherent light to impinge on the sample, a second optical chain to direct the scattered light onto a diffraction grating, and a third optical chain to direct the diffracted light onto detection array. The diffraction grating is a plurality of alternating-slope stairsteps, wherein the portion of the step disposed parallel to the base of the diffraction grating is disposed so as to be orthogonal to the path of the scattered light from the second optical chain. The zeroth-order fringe is selected by a slit and directed onto camera. The resultant interferogram is Fourier transformed to produce a representation of the Raman spectrum. | 01-29-2015 |
20150008123 | ELECTROWETTING ON DIELECTRIC USING GRAPHENE - An electrowetting device and a method of electrowetting may be provided. An electrode may be provided. The electrode has a graphene layer having a first side and a second side that opposes the first side. The electrode also has a dielectric layer disposed on the first side of the graphene layer. A liquid droplet is disposed on the dielectric layer. A voltage is applied through the droplet and the electrode. A contact angle between the dielectric layer and an edge of the liquid droplet contacting the dielectric layer changes in response to the applied voltage. | 01-08-2015 |
20140379242 | AUTONOMOUS OPERATION OF ELECTRONICALLY CONTROLLED INTERNAL COMBUSTION ENGINES ON A VARIETY OF FUELS AND/OR OTHER VARIABILITIES USING ION CURRENT AND/OR OTHER COMBUSTION SENSORS - A system and method to enable electronically controlled internal combustion engines to self-adjust parameters and operate properly on different fuels that have wide ranges of physical and chemical properties. Input from a sensor is utilized that gives a signal indicative of the combustion process. The ECU processes the signal and readjusts the engine operating parameters to achieve its operating goals. | 12-25-2014 |
20140378541 | Synthetic Epigallocatechin Gallate (EGCG) Analogs - Synthetic polyphenolic compounds of formula (I), their modes of synthesis, and pharmaceutical compositions thereof are provided herein. Use of the compounds and compositions described herein for treating cancer and for treating metabolic disorders is also provided. | 12-25-2014 |
20140371826 | LIGHT THERAPY TREATMENT - An exemplary method includes selecting at least one light source configured to generate light at a particular wavelength and applying the light to tissue following an ischemic event. Applying the light to the tissue inhibits cytochrome c oxidase activity. Another exemplary method includes selecting at least one light source configured to generate light at a particular wavelength and applying the light to tissue following an ischemic event and prior to either reoxygenation of the tissue or clinical intervention to reduce cell damage. An exemplary light therapy device includes at least one light source configured to generate light having a wavelength of at least one of approximately 730-770 nm, 850-890 nm, 880-920 nm, and 930-970 nm. | 12-18-2014 |
20140356367 | MONOPHOSPHORYLATED LIPID A DERIVATIVES - The present invention provides for monophosphorylated lipid A derivatives and carbohydrate derivatives that are useful as agents in the treatment of diseases and conditions, including cancers. Also provided are pharmaceutical compositions comprising one or more compounds of Formula I-IV. In addition, methods for the treatment of cancers are provided. | 12-04-2014 |
20140349889 | FORMATION OF A SUPRA-MONOLAYER NANOPATTERN AND ITS USES - The present disclosure discloses a method to prepare a supra-monolayer nanopattern and its uses. | 11-27-2014 |
20140342389 | METHOD AND COMPOSITION FOR A PROTEIN TRANSDUCTION TECHNOLOGY AND ITS APPLICATIONS - A protein transduction method for efficiently delivery of exogenous proteins into mammalian cells is invented, which has the capability of targeting different cellular compartments and protection from degradation of the delivered proteins from cellular proteases. A composition for treat proteins has cation reagents, lipids and enhancers in a carrier. The method can be used in a number of ways including: production of large quantities of properly folded, post-translationally modified proteins using mammalian cell machinery, a in-cell fluorescence spectroscopy and imaging using small molecule fluorophores and a in-cell NMR spectroscopy using living mammalian cells. The method permits cell biology at atomic resolution that is physiologically and pathological relevant and permits protein therapy to treat human diseases. The method can also be used to deliver exogenous protein inside mammalian cells, wherein the exogenous proteins follow a similar secretion pathway as that of the endogenous protein. | 11-20-2014 |
20140255803 | GRAPHENE SUPPORTED BIFUNCTIONAL CATALYSTS - The present disclosure discloses graphene supported bifunctional catalysts and metal-air batteries comprising the same. In one aspect, a metal-air battery comprises a metal anode, a cathode, an electrolyte disposed between the metal anode and the cathode, and a catalyst on the cathode. The catalyst reduces both the charge overpotential and discharge overpotential of the battery. The catalyst is disposed on a graphene support. | 09-11-2014 |
20140242695 | PROTEIN-INDUCED PLURIPOTENT CELL TECHNOLOGY AND USES THEREOF - A method of generating protein-induced pluripotent stem cells by delivering bacterially expressed reprogramming proteins into nuclei of starting somatic cells using the QQ-protein transduction technique, repeating several cell reprogramming cycles for creating reprogrammed protein-induced pluripotent stem cells, moving the reprogrammed cells into a feeder-free medium for expansion, and expanding and passaging the reprogrammed cells in a whole dish for generating homogeneous piPS cells. Also provided are the piPCS cells formed using this method and uses thereof. | 08-28-2014 |
20140234550 | ATOMIC LAYER DEPOSITION OF TRANSITION METAL THIN FILMS - An atomic layer deposition method for forming metal films on a substrate comprises a deposition cycle including:
| 08-21-2014 |
20140221412 | THERAPEUTIC COMPOUNDS AND METHODS - The invention provides compounds of formula I: and salts thereof. The invention also provides pharmaceutical compositions comprising a compound of formula I, processes for preparing compounds of formula I, intermediates useful for preparing compounds of formula I and therapeutic methods for treating cancer using compounds of formula I. | 08-07-2014 |
20140213802 | (-)-Epigallocatechin Gallate Derivatives for Inhibiting Proteasome - A method of reducing tumor cell growth, the method including administering an effective amount of a compound having the formula: | 07-31-2014 |
20140205538 | VACCINES TARGETING CELLULAR DEATH RECEPTORS - The invention provides therapeutics and methods to induce a mammalian host, including a human, to produce antibodies, which agonize death receptors and cause the apoptotic death of target cells within the host's body. The therapeutics are vaccine compositions, including genetic vaccines encoding death receptor antigens of the tumor necrosis factor receptor family. Also provided are means and methods for overcoming host immunological tolerance to death receptors. The vaccines are useful against cancer cells and other death receptor bearing target cells within the host, and can be used in both therapeutic and prophylactic settings. The vaccines are also useful for diagnostic testing of the immunocompetence of a host. | 07-24-2014 |
20140183669 | RESONANT SENSOR WITH ASYMMETRIC GAPPED CANTILEVERS - A resonant sensor is provided. The resonant sensor may have a structure including a base portion, a mass portion, and a mechanical beam connecting the base portion to the mass portion. In addition, the structure may include a first sensing beam formed from a sensing material responsive to mechanical strain where a gap is formed between the sensing beam and the mechanical beam. | 07-03-2014 |
20140172385 | Genetic, Metabolic and Biochemical Pathway Analysis System and Methods - Identifying pathways that are significantly impacted in a given condition is a crucial step in the understanding of the underlying biological phenomena. All approaches currently available for this purpose calculate a p-value that aims to quantify the significance of the involvement of each pathway in the given phenotype. These p-values were previously thought to be independent. Here, we show that this is not the case, and that pathways can affect each other's p-values through a “crosstalk” phenomenon that affects all major categories of existing methods. We describe a novel technique able to detect, quantify, and correct crosstalk effects, as well as identify novel independent functional modules. We assessed this technique on data from four real experiments coming from three phenotypes involving two species. | 06-19-2014 |
20140172384 | Genetic, Metabolic and Biochemical Pathway Analysis System and Methods - Identifying pathways that are significantly impacted in a given condition is a crucial step in the understanding of the underlying biological phenomena. All approaches currently available for this purpose calculate a p-value that aims to quantify the significance of the involvement of each pathway in the given phenotype. These p-values were previously thought to be independent. Here, we show that this is not the case, and that pathways can affect each other's p-values through a “crosstalk” phenomenon that affects all major categories of existing methods. We describe a novel technique able to detect, quantify, and correct crosstalk effects, as well as identify novel independent functional modules. We assessed this technique on data from four real experiments coming from three phenotypes involving two species. | 06-19-2014 |
20140166875 | SYSTEMS AND METHODS FOR HIGH THROUGHPUT SOLVENT ASSISTED IONIZATION INLET FOR MASS SPECTROMETRY - A multiplex system and method for achieving high throughput analysis of samples using solvent assisted ionization inlet includes an ionizing system with a heated inlet channel and a pressure differential across the inlet channel, pipet tips serially aligned with the inlet to a mass spectrometer, and a system of mapping data generated by mass spectrometry. | 06-19-2014 |
20140161977 | Synthesis and Characterization of First Row Transition Metal Complexes Containing alpha-keto Hydrazonate Ligands as Potential Precursors for Use in Metal Film Deposition - A compound that is useful for forming a metal by reaction with a reducing agent is described by formula (I): | 06-12-2014 |
20140150887 | OPTOFLUIDIC TWEEZERS - In a method of moving droplets, local heat is applied to a surface portion of a droplet for an amount of time sufficient to create a Marangoni flow in the droplet. Droplets are suspended in an emulsion in a carrier liquid on a substrate. A laser beam is used to move one of the droplets. the droplet consists of a first substance and a carrier liquid consists of a second substance that is not mixable with the first substance. The droplet is placed in the carrier liquid, and the mixture is emulsified. The emulsified mixture is placed on a substrate. Then the local heat is applied to the surface of the droplet. The first substance may include oil and the second substance may include water. | 06-05-2014 |
20140141992 | NEOEPITOPE DETECTION OF DISEASE USING PROTEIN ARRAYS - A biosensor for use in detecting the presence of diseases, the biosensor comprising a detector for detecting a presence of at least one marker indicative of a specific disease. A method of determining efficacy of a pharmaceutical for treating a disease or staging disease by administering a pharmaceutical to a sample containing markers for a disease, detecting the amount of at least one marker of the disease in the sample, and analyzing the amount of the marker in the sample, whereby the amount of marker correlates to pharmaceutical efficacy or disease stage. Markers for gynecological disease. An immune-imaging agent comprising labeled antibodies, whereby the labeled antibodies are isolated and reactive to proteins overexpressed in vivo. Informatics software for analyzing the arrays, the software including analyzing means for analyzing the arrays. | 05-22-2014 |
20140128355 | BACLOFEN SOLUTION FOR LOW-VOLUME THERAPEUTIC DELIVERY - A high concentration baclofen solution is provided suitable for therapeutic use in a medical setting. A high concentration solution of baclofen in multivalent physiological ion solution such as artificial cerebrospinal fluid is provided with concentrations of baclofen of 10 mg/ml. Artificial cerebrospinal fluid is particularly advantageous as a baclofen solvent. A medical package is also provided for baclofen delivery to patients suffering from spasticity. | 05-08-2014 |
20140121265 | Restoration of Visual Responses by In Vivo Delivery of Rhodopsin Nucleic Acids - Nucleic acid vectors encoding light-gated cation-selective membrane channels, in particular channelrhodopsin-2 (Chop2), converted inner retinal neurons to photosensitive cells in photoreceptor-degenerated retina in an animal model. Such treatment restored visual perception and various aspects of vision. A method of restoring light sensitivity to a retina of a subject suffering from vision loss due to photoreceptor degeneration, as in retinitis pigmentosa or macular degeneration, is provided. The method comprises delivering to the subject by intravitreal or subretinal injection, the above nucleic acid vector which comprises an open reading frame encoding a rhodopsin, to which is operatively linked a promoter and transcriptional regulatory sequences, so that the nucleic acid is expressed in inner retinal neurons. These cells, normally light-insensitive, are converted to a light-sensitive state and transmit visual information to the brain, compensating for the loss, and leading to restoration of various visual capabilities. | 05-01-2014 |
20140120038 | NANOPARTICLES FOR IMAGING AND TREATING CHLAMYDIAL INFECTION - Compositions of nanoparticles and targeting moieties for imaging and treating Chlamydial infection are provided, including nanoparticles conjugated to folic acid and comprising at least one antibiotic effective against | 05-01-2014 |
20140100173 | Nitrile-containing enzyme inhibitors and ruthenium complexes thereof - The invention provides nitrile-containing protease inhibitors caged to ruthenium compounds. The nitrile-caged ruthenium compounds provide inactivated inhibitors that can be delivered to surface or site for activation, for example, but exposure to light. The invention also provides methods for delivering protease inhibitors to subjects for the therapeutic treatment of conditions such as cancer. | 04-10-2014 |
20140081601 | MODEL-BASED HELMET DESIGN TO REDUCE CONCUSSIONS - A system and method for designing a helmet to reduce mild traumatic brain injury sustained by a user during primary or secondary head impact include modeling a helmeted head including a head, brain, and helmet using a finite element computer model, the finite element computer model including material properties for the head, brain structures, and helmet and estimating at least intracranial pressure, brain strain and strain rate in response to an impact; and selecting at least one of a helmet cushion material and helmet shell material to limit at least one of intracranial pressure, brain strain and strain rate to a corresponding threshold for an associated impact. | 03-20-2014 |
20140081556 | USING ION CURRENT SIGNAL FOR SOOT AND IN-CYLINDER VARIABLE MEASURING TECHNIQUES IN INTERNAL COMBUSTION ENGINES AND METHOD FOR DOING THE SAME - A system and method is provided for the use of the ion current signal characteristics for onboard cycle-by-cycle, cylinder-by-cylinder measurement, for example soot measurement, load measurement such as indicated or brake mean effective pressure, or fuel consumption measurement in an internal combustion engine. The system may acquire an ion current signal, measures one or more of soot, load, fuel consumption and may control the engine operating parameters accordingly. | 03-20-2014 |
20140058120 | TRI-SUBSTITUTED 2-BENZHYDRYL-5-BENZYLAMINO-TETRAHYDRO-PYRAN-4-OL AND 6-BENZHYDRYL-4-BENZYLAMINO-TETRAHYDRO-PYRAN-3-OL ANALOGUES, AND NOVEL 3,6-DISUBSTITUTED PYRAN DERIVATIVES - Novel 3,6-disubstituted pyrans, optionally with a further substituent at the 4-position, are monoamine reuptake inhibitors with activity profiles of anti-depressants. | 02-27-2014 |
20140027631 | Systems and Methods Extending the Laserspray Ionization Mass Spectrometry Concept from Atmospheric Pressure to Vacuum - Disclosed herein are systems and methods that allow analysis of macromolecular structures using laserspray ionization at intermediate pressure or high vacuum using commercially available mass spectrometers with or without modification and with the application of heat. The systems and methods produce multiply-charged ions for improved analysis in mass spectrometry. | 01-30-2014 |
20140027201 | ACOUSTIC METAMATERIALS - Metamatenal members for absorbing sound and pressure, and modular systems built of metamaterial members are provided. The metamaterial member includes an outer mass. The outer mass can have a cavity formed therein in which a stem coupled to an inner mass is disposed, or the outer mass can be solid and contain an inner mass embedded therein. The inner mass can include an inner core and an outer shell. Multiple metamaterial members can be attached to form a modular system for absorption of sound and pressure. | 01-30-2014 |
20130337544 | METHODS AND COMPOSITION FOR THE IDENTIFICATION OF ANTIBIOTICS THAT ARE NOT SUSCEPTIBLE TO ANTIBIOTIC RESISTANCE - Compositions are provided to identify functional mutant ribosomes that may be used as drug targets. The compositions allow isolation and analysis of mutations that would normally be lethal and allow direct selection of rRNA mutants with predetermined levels of ribosome function. The compositions of the present invention may be used to identify antibiotics to treat a large number of human pathogens through the use of genetically engineered rRNA genes from a variety of species. The invention further provides novel plasmid constructs to be used in the methods of the invention. | 12-19-2013 |
20130331559 | NOVEL TARGETS FOR THE IDENTIFICATION OF ANTIBIOTICS THAT ARE NOT SUSCEPTIBLE TO ANTIBIOTIC RESISTANCE - To identify conserved and variable regions of the 16 S rRNA, an instant evolution experiment was performed on the entire 16 S rRNA. Analysis of these mutants identified regions that are required for function. These conserved sequences may be used as targets for pharmaceuticals that are taxonomically specific and which are refractory to the development of drug resistance. | 12-12-2013 |
20130330736 | METHODS AND COMPOSITIONS FOR THE IDENTIFICATION OF ANTIBIOTICS THAT ARE NOT SUSCEPTIBLE TO ANTIBIOTIC RESISTANCE IN PSEUDOMONAS AERUGINOSA - The “instant evolution” system was initially developed in | 12-12-2013 |
20130330473 | Atomic Layer Deposition of Transition Metal Thin Films Using Boranes as the Reducing Agent - A method for forming a metal comprises contacting a compound having formula 1 with a compound having formula 2 with an amine borane: | 12-12-2013 |
20130263449 | CHECK VALVE DIAPHRAGM MICROPUMP - A micropump device including a first wafer and a second wafer attached to the first wafer. The first and second wafers are configured to define a chamber therebetween having a predetermined volume. A third wafer is attached to the second wafer to define an inlet section and an outlet section in fluid communication with the chamber. At least one of the second and third wafers are formed to define a moveable diaphragm configured to change the predetermined volume of the chamber for pumping a fluid between the inlet section and the outlet section. | 10-10-2013 |
20130259833 | AAV-Mediated Subcellular Targeting of Heterologous Rhodopsins in Retinal Ganglion Cells - Microbial type rhodopsins, such as the light-gated cation-selective membrane channel, channelrhodopsin-2 (Chop2/ChR2) or the ion pump halorhodopsin (HaloR) are expressed in retinal ganglion cells upon transduction using recombinant AAV vectors. Selective targeting of these transgenes for expression in discrete subcellular regions or sites is achieved by including a sorting motif in the vector that can target either the central area or surround (off-center) area of these cells. Nucleic acid molecules comprising nucleotide sequences encoding such rhodopsins and sorting motifs and their use in methods of differential expression of the transgene are disclosed. These compositions and methods provide significant improvements for restoring visual perception and various aspects of vision, particular in patients with retinal disease. | 10-03-2013 |
20130230807 | METHOD OF FABRICATING TRANSPARENT ANTI-REFLECTIVE ARTICLE - A method of fabricating an anti-reflective optically transparent structure includes the steps of providing an optically transparent substrate having a first refractive index and a first surface; and forming an anti-reflective layer within the first surface of the transparent substrate. The anti-reflective layer is made by forming a nano-scale pattern within the first surface defining a subwavelength nano-structured second surface of the anti-reflective layer including a plurality of protuberances having a predetermined maximum distance between adjacent protuberances and a predetermined height for a given wavelength such that the anti-reflective layer includes a second refractive index lower than the first refractive index to minimize light diffraction and random scattering therethrough. The predetermined height is approximately equal to a quarter of the given wavelength divided by the second refractive index. One of nanosphere lithography, deep ultra-violet photolithography, electron beam lithography, and nano-imprinting may be used to form the anti-reflective layer. | 09-05-2013 |
20130214154 | SYSTEM AND METHOD FOR IONIZATION OF MOLECULES FOR MASS SPECTROMETRY AND ION MOBILITY SPECTROMETRY - An ionizing system includes a channel having an inlet disposed in a first pressure region and an outlet disposed in a second pressure region, a pressure of the first pressure region being greater than a pressure of the second pressure region. A heater is coupled to the channel and configured to heat the channel. A device is configured to introduce an analyte into the channel where the analyte is ionized. | 08-22-2013 |
20130211752 | SOFTWARE POWER ANALYSIS - Methods and systems for providing software power analysis. In an example, a computerized method, and system for performing the method includes determining at least one performance monitoring counter value for at least one processor. A frequency of operation is determined for the processor. A power dissipation level is calculated for the processor using a computing device and the power dissipation level is provided as an output. In an example, at least one application programming interface is received. In an example, at least one application is run. In an example, a default file is generated. The default file contains at least one power model parameter and at least one estimated frequency of operation. In an example, several performance monitoring counter values are generated for at least one core in a multi-core processor. In an example, a software power analyzer control thread is executed. | 08-15-2013 |
20130173096 | GUIDANCE AND CONTROL SYSTEM FOR UNDER-ACTUATED MARINE SURFACE SHIPS AND OTHER AUTONOMOUS PLATFORMS - A computer implemented method for guiding an under-actuated marine surface vessel in tracking a desired trajectory comprises expressing a predetermined vessel trajectory as a set of straight line segments, determining a desired current line segment, and determining the vessel's current position. A cross-track error and the derivative of the cross-track error are then determined. Next, a radius R of the line-of-sight (LOS) circle using a newly introduced exponential function is determined. Intersection points M and N between the LOS circle and the current desired line segment are determined. A desired heading angle is determined as the angle between the line of sight and a predetermined fixed reference line. A drift detection algorithm is built into the proposed guidance scheme to detect situations whereby the ship moves parallel to its desired trajectory for an extended period of time without being able to correct for the cross track error. | 07-04-2013 |
20130164456 | THERMALLY STABLE VOLATILE PRECURSORS - A method of forming a thin film on a substrate which includes a step of contacting a surface with a precursor compound having a transition metal and one or more alkyl-1,3-diazabutadiene ligands is provided. The resulting modified surface is then contacted with an activating compound. | 06-27-2013 |
20130150260 | PEPTIDE ANTIMICROBIALS - Provided are methods and compositions for in vivo display and screening of peptides for antimicrobial activity. The methods can include expressing a random peptide library in a microbial cell culture and identifying clones in which microbial cell growth or survival is affected by the peptide expressed by that clone. Also provided are peptide antimicrobials identified using these methods and compositions. | 06-13-2013 |
20130136697 | INJECTABLE DENDRIMER HYDROGEL NANOPARTICLES - The invention discloses injectable hydrogels which are in the form of crosslinked nano beads or particle in the size range 5 nm to 10 μm, comprising PAMAM dendrimer with asymmetrical peripheral end groups such that one of the terminal groups is involved in formation of hydrogel and the other in involved in the conjugation of drugs or imaging agents and their methods of preparation. The said gel is formed by reaction of the PAMAM dendrimer with asymmetrical end groups with other polymer wherein the other polymer is selected from the group of linear, branched, hyperbranched or star shaped polymers with functionalized terminal groups. The PAMAM dendrimer with asymmetrical terminal groups consists of a Generation 2 and above PAMAM dendrimer with symmetrical end groups modified using the amino acids or their modified forms. The gel disclosed in the present invention is formed as small crosslinked particles in the size range 25 nm to 10 μm and is suitable for injectable delivery of hydrogel to any of the body orifices, tissues by intramuscular or subcutaneous route and ocular delivery for the purpose of therapeutic treatment and imaging. | 05-30-2013 |
20130122027 | NEOEPITOPE DETECTION OF DISEASE USING PROTEIN ARRAYS - A biosensor for use in detecting the presence of diseases, the biosensor comprising a detector for detecting a presence of at least one marker indicative of a specific disease. A method of determining efficacy of a pharmaceutical for treating a disease or staging disease by administering a pharmaceutical to a sample containing markers for a disease, detecting the amount of at least one marker of the disease in the sample, and analyzing the amount of the marker in the sample, whereby the amount of marker correlates to pharmaceutical efficacy or disease stage. Markers for gynecological disease. An immuno-imaging agent comprising labeled antibodies, whereby the labeled antibodies are isolated and reactive to proteins overexpressed in vivo. Informatics software for analyzing the arrays, the software including analyzing means for analyzing the arrays. | 05-16-2013 |
20130095487 | Interferon-Gamma Response as a Diagnostic Test for Persistent Chlamydial Infections - The present invention provides a non-invasive, sensitive, and convenient diagnostic test for persistent Chlamydial infection and diseases arising from persistent Chlamydial infection. The present invention also provides kits for diagnosis of persistent Chlamydial infection. | 04-18-2013 |
20130018635 | SYSTEM AND METHODS FOR THREE DIMENSIONAL MOLECULAR STRUCTURAL ANALYSIS - The present invention relates to methods and systems for the accurate prediction of nucleic acid, e.g., RNA and DNA, and other macromolecular and biomolecular three-dimensional structure from sequence and constraint information. | 01-17-2013 |
20120295927 | METHODS OF USING SELECTIVE CHEMOTHERAPEUTIC AGENTS FOR TARGETING TUMOR CELLS - A method for treating cancer tumors, particularly ovarian cancer tumors, is described, where fused cyclic pyrimidine having a cancer treating ability is selectively delivered to an FR expressing cancerous tumor. | 11-22-2012 |
20120283459 | METALOXIDE - Zr02 CATALYSTS FOR THE ESTERIFICATION AND TRANSESTERIFICATION OF FREE FATTY ACIDS AND TRIGLYCERIDES TO OBTAIN BIO-DIESEL - Mixed metal oxide catalysts (ZnO, CeO, La2O3, NiO, Al203, Si02, TiO2, Nd2O3, Yb2O3, or any combination of these) supported on zirconia (ZrO2) or hydrous zirconia are provided. These mixed metal oxide catalysts can be prepared via coprecipitation, impregnation, or sol-gel methods from metal salt precursors with/without a Zirconium salt precursor. Metal oxides/ZrO2 catalyzes both esterification and transesterification of oil containing free fatty acids in one batch or in single stage. In particular, these mixed metal oxides supported or added on zirconium oxide exhibit good activity and selectivity for esterification and transesterification. The low acid strength of this catalyst can avoid undesirable side reaction such as alcohol dehydration or cracking of fatty acids. Metal oxides/ZrO2 catalysts are not sensitive to any water generated from esterification. Thus, esterification does not require a water free condition or the presence of excess methanol to occur when using the mixed metal oxide catalyst. The FAME yield obtained with metal oxides/ZrO2 is higher than that obtained with homogeneous sulfuric acid catalyst. Metal oxides/ZrO2 catalasts can be prepared as strong pellets and in various shapes for use directly in a flow reactor. Furthermore, the pellet has a strong resistance toward dissolution to aqueous or oil phases. | 11-08-2012 |
20120269813 | POLYCLONAL BISPECIFIC ANTIBODY COMPOSITIONS AND METHOD OF USE - The invention relates to compositions and methods for treating a host infected with a pathogen. The composition comprising a population of polyclonal bispecific binding molecules that can target and eliminate a host cell infected with the pathogen. Methods for activating and arming cytotoxic immune cells with the composition for use in treating a patient infected with a pathogen are also provided. | 10-25-2012 |
20120258481 | CROSS-LINKING ATP ANALOGS - An adenosine 5′-triphosphate analogs modified at the gamma-phosphate with a reactive reagent. A method of forming the analog by activating a 4-amino benzoic acid, incubating the activated acid to obtain an amine, and coupling the amine with ATP in the presence of water soluble EDCI. A method of detecting the efficacy of a therapeutic by adding a gamma-phosphate modified ATP analog to a protein substrate, reacting the target proteins with the ATP analog, and analyzing the resulting cross-linked product, wherein the amount of product present correlates to the efficacy of the therapeutic is also provided. | 10-11-2012 |
20120232135 | (-)-Epigallocatechin Gallate Derivatives for Inhibiting Proteasome - A method of reducing tumor cell growth, the method including administering an effective amount of a compound having the formula: | 09-13-2012 |
20120133774 | AUTOMATED VIDEO SURVEILLANCE SYSTEMS - A video surveillance system includes a plurality of video sources, at least one processing server in communication with the video sources, and at least one monitoring station viewing video from the video sources. The video sources are distributed over a target area to be monitored by the surveillance system and are attached to a video network. The processing server allocates bandwidth to the video sources with an accuracy function which provides event/object detection accuracy as a function of image/video quality transferred over the network. The image accuracy is the accuracy with which the processing server identifies features in a video image. Bandwidth is allocated by optimizing the overall event/object detection accuracy by adjusting image/video quality for each video source optionally subject to the dynamic network conditions experienced by each video source. | 05-31-2012 |
20120121589 | MODIFIED EGFR ECTODOMAIN - A protein that attenuates EGFR and/or EGFR family members comprises a modified EGFR ectodomain. The protein inhibits signaling via the EGFR and/or EGFR family members. The protein includes a portion of the EGFR (or EGFR family member) and the “U” region epitope of EGFR related protein (ERRP), wherein the portion of the EGFR is operable to bind a ligand of EGFR. Also included are nucleic acids encoding such proteins. Attenuating EGFR signaling can include inhibiting the EGFR and/or EGFR family members and to provide antiproliferative activity. The present proteins and expression of nucleic acids encoding these proteins can regulate cellular growth and can be used to treat tumors and cancerous cells that express one or more of the EGFR and EGFR family members. | 05-17-2012 |
20120108815 | BIFUNCTIONAL/POLYFUNCTIONAL DOPAMINE D2/D3 AGONIST AS NEUROPROTECTIVE AGENTS FOR TREATMENT OF NEURODEGENERATIVE DISEASES - A precursor for the deposition of a thin film by atomic layer deposition is provided. The compound has the formula M | 05-03-2012 |
20120107828 | METHOD FOR IDENTIFYING A SUBPOPULATION OF MAMMALIAN CELLS WITH DISTINCTIVE RIBOSOME TRANSLATION PROFILES - The present invention generally relates to subpopulations of mammalian cells with distinctive ribosome translational profiles, i.e. translational activities. The present invention further relates to methods for identifying and isolating such cells, kits comprising the same, or methods which utilize different translational activities of these subpopulations of mammalian cells. | 05-03-2012 |
20120096631 | OMNI-DIRECTIONAL ANGULAR ACCERATION REDUCTION FOR PROTECTIVE HEADGEAR - Protective headgear includes an outer shell rotatable relative to an inner shell via a thin layer of elastically and/or plastically yielding material disposed between and secured to the inner and outer shells. The yielding material deforms continuously but non-linearly at least in the tangential or shear direction to mitigate angular acceleration of the head during an impact. The yielding material prevents the inner and outer shells from separating or stopping suddenly to avoid imparting a large angular acceleration to the head. In one embodiment, a protective helmet includes an outer shell secured to an inner shell by a yielding material that elastically deforms continuously but non-linearly when subjected to an angular acceleration below a first threshold and plastically deforms when subjected to an angular acceleration above the first threshold. | 04-26-2012 |
20120095117 | GALECTIN-3 nsSNP MARKER FOR CANCER - A diagnostic biomarker including a mechanism for determining a patient's propensity to develop cancer. A diagnostic kit for determining a patient's propensity to develop cancer. A method of predicting both a patient's and a population's propensity to develop cancer, by detecting the presence of an H | 04-19-2012 |
20120093718 | LIPOSOMAL NANOPARTICLES AND OTHER FORMULATIONS OF FENRETINIDE FOR USE IN THERAPY AND DRUG DELIVERY - Formulations of neutral retinoids, in particular fenretinide (HPR) in the form of lipid nanoparticles, solid dipersions and emulsions are disclosed. These compositions are used to treat diseases that are amenable to treatment by HPR, such as neoplastic diseases by achieving higher and more prolonged concentrations of HPR in the subject. The key steps for preparing lipid nanovesicles of HPR include mixing and sonication, sterile filtration, without or without lyophilization for long-term stable storage, and employ processes and materials that are scalable from the laboratory to the manufacturing level. The formulation are suitable for injection into human or animal patients without causing allergic or hypersensitivity responses by avoiding chemical surfactants and animal sources of phospholipids in their manufacture. | 04-19-2012 |
20120085903 | MASS SPECTOMETRY USING LASERSPRAY IONIZATION - Disclosed herein are systems and methods for mass spectrometry using laserspray ionization (LSI). LSI can create multiply-charged ions at atmospheric pressure for analysis and allows for analysis of high molecular weight molecules including molecules over | 04-12-2012 |
20120058270 | THERMALLY STABLE VOLATILE FILM PRECURSORS - A precursor for the deposition of a thin film by atomic layer deposition is provided. The compound has the formula MxLy where M is a metal and L is an amidrazone-derived ligand or an amidate-derived ligand. A process of forming a thin film using the precursors is also provided. | 03-08-2012 |
20120046182 | NEOEPITOPE DETECTION OF DISEASE USING PROTEIN ARRAYS - A biosensor for use in detecting the presence of diseases, the biosensor comprising a detector for detecting a presence of at least one marker indicative of a specific disease. A method of determining efficacy of a pharmaceutical for treating a disease or staging disease by administering a pharmaceutical to a sample containing markers for a disease, detecting the amount of at least one marker of the disease in the sample, and analyzing the amount of the marker in the sample, whereby the amount of marker correlates to pharmaceutical efficacy or disease stage. Markers for gynecological disease selected from the list in Table 8. An immuno-imaging agent comprising labeled antibodies, whereby the labeled antibodies are isolated and reactive to proteins overexpressed in vivo. Informatics software for analyzing the arrays of claim | 02-23-2012 |
20120028893 | Adenovirus 36 E4 ORF 1 Gene and Protein and Their Uses - Expression of the E4 orf 1 gene of Ad-36 alone has been discovered to be responsible for the increased insulin sensitivity observed in Ad-36 infected animals, including increased adipogenesis. Ad-36 E4 orf 1 protein can be used to increase insulin sensitivity and ameliorate diabetes. Additionally, drugs that mimic the action of Ad-36 E4 orf 1 protein could be found. Ad-36 E4 orf 1 could also be used to increase fat cells in lipodystrophy. We have also discovered that Ad-36 infection in human skeletal muscle cells increased differentiation and insulin independent glucose uptake. It is expected that infection with Ad-36 E4 orf 1 gene will also cause these effects. | 02-02-2012 |
20120004428 | Tri-Substituted 2-Benzhydryl-5-Benzylamino-Tetrahydro-Pyran-4-OL and 6-Benzhydryl-4-Benzylamino-Tetrahydro-Pyran-3-OL Analogues, and Novel 3,6-Disubstituted Pyran Derivatives - Novel 3,6-disubstituted pyrans, optionally with a further substituent at the 4-position, are monoamine reuptake inhibitors with activity profiles of anti-depressants. | 01-05-2012 |
20120003155 | DENDRIMER BASED NANODEVICES FOR THERAPEUTIC AND IMAGING PURPOSES - A nanodevice composition including N-acetyl cysteine linked to a dendrimer, such as a PAMAM dendrimer or a multiarm PEG polymer, is provided. Also provided is a nanodevice for targeted delivery of a compound to a location in need of treatment. The nanodevice includes a PAMAM dendrimer or multiarm PEG polymer, linked to the compound via a disulfide bond. There is provided a nanodevice composition for localizing and delivering therapeutically active agents, the nanodevice includes a PAMAM dendrimer or multiarm PEG polymer and at least one therapeutically active agent attached to the PAMAM dendrimer or multiarm PEG polymer. A method of site-specific delivery of a therapeutically active agent, by attaching a therapeutically active agent to a PAMAM dendrimer or multiarm PEG polymer using a disulfide bond, administering the PAMAM dendrimer or multiarm PEG polymer to a patient in need of treatment, localizing the dendrimer or multiarm PEG polymer to a site in need of treatment, and releasing the therapeutically active agent at the site in need of treatment. | 01-05-2012 |
20110236484 | Genus-Wide Chlamydial Peptide Vaccine Antigens - Peptides generated from a random library that are bound by a monoclonal antibody to Chlamydial glycolipid exoantigen (GLXA) and thus mimic this antigen are disclosed. Peptides that correspond to antigen-binding regions of an anti-idiotypic antibody (mAb2) specific for anti-GLXA antibody (Ab1) which act as molecular mimics of GLXA are also disclosed used as immunogens to induce broadly reactive genus-specific anti-chlamydial antibodies. These peptides and immunogenic DNA encoding the mAb2-like peptides, microparticle or nanoparticle formulations and other formulations of these peptides are disclosed as are methods for immunizing subjects to obtain genus-specific anti-chlamydial antibodies and to treat or prevent | 09-29-2011 |
20110224312 | ENGINEERING POROUS PARTICLES OF WATER SOLUBLE THERAPEUTICS FOR PRESSURIZED METERED-DOSE INHALER FORMULATIONS - The subject matter disclosed herein relates to methods for engineering porous particles of water soluble therapeutics with enhanced physical stability and aerosol characteristics in hydrofluoroalkane (HFA)-based pressurized metered-dose inhaler (pMDI) formulations. | 09-15-2011 |
20110224275 | INHIBITORS OF MATRIX METALLOPROTEINASES - The present invention provides novel compounds of formulas I-IX, as described herein. Also provided are compositions of compounds of formulas I-IX, methods of making compounds of formulas I-IX, and methods of using compounds of formulas I-IX. The compounds of the invention can be used to inhibit matrix metalloproteinases, and are useful to treat conditions and diseases associated therewith. | 09-15-2011 |
20110223216 | Nanoparticles and Porous Particles and Methods of Making the Same - The subject matter disclosed herein relates to compositions and methods for engineering porous particles for aerosol formulations for pulmonary drug delivery. Certain embodiments disclosed herein further relate to methods for stabilizing suspension-based formulations in hydrofluoroalkane propellants with nanoparticles. | 09-15-2011 |
20110212472 | Asbestos Exposure, Pleural Mesothelioma and Osteopontin Levels - The present invention provides diagnostic and disease progression or recurrence prediction methods based on osteopontin levels in a biological sample. | 09-01-2011 |
20110191874 | COMPOSITIONS AND METHODS FOR DETECTING AND MODULATING CELL DEATH BY A TRANSLATION REGULATED GENE EXPRESSION SYSTEM - The technology relates to a nucleic acid expression cassette comprising a TR element encoding an mRNA molecule that is translated in stressed and/or dying cells, and a nucleotide sequence operably linked to the TR element, that is a first open reading frame (ORF) sequence and encodes a polypeptide or a fragment thereof and is co-translated with the TR element. The technology further relates to mammalian cells and a transgenic animal comprising such expression cassette. Further included are kits comprising the expression cassette, and methods for determining toxicity, and killing a target cell | 08-04-2011 |
20110152210 | POLYPHENOL COMPOUNDS FOR INHIBITING PROTEASOME AND USES THEREOF - Synthetic polyphenolic compounds of formula (I), their modes of synthesis, and pharmaceutical compositions thereof are provided herein. Use of the compounds and compositions described herein for inhibiting proteasomal activity and for treating cancer is also provided. | 06-23-2011 |
20110114233 | DEVELOPMENT OF A HIGH STRENGTH HIGH TOUGHNESS BAINITIC STEEL - A bainitic steel with simultaneous high yield strength and high fracture toughness includes at least 5 volume percent austenite as well as iron, carbon, and silicon. The silicon is present in an amount of at least 1.5 weight percent of total weight of the bainitic steel. A method of forming the steel by austempering is also provided. | 05-19-2011 |
20110034422 | DENDRIMERS FOR SUSTAINED RELEASE OF COMPOUNDS - Dendrimer-based compositions and methods are provided, that are useful for administering pharmaceutical compositions to target cells and tissues for treatment of ocular diseases including macular degeneration, diabetic retinopathy, and retinitis pigmentosa. | 02-10-2011 |
20110021748 | Non-Natural Peptides as Models for the Development of Antibiotics - Described herein are methods of screening one of the RNA hairpins in the small ribosomal subunit of bacteria to identify peptides that bind to it. The RNA hairpin target may be the 970 loop (aka helix 31 (h31)) or a modified version thereof. The identified peptides may inhibit protein synthesis and, therefore, may be used as a model for new antibiotics. | 01-27-2011 |
20110020849 | BIOMARKERS FOR DIAGNOSTIC AND THERAPEUTIC METHODS - Erythrocyte ATP-release modulators and composition and methods for their use as biomarkers of glucose processing or vascular disorders, as well as methods for screening to identify to modulators; methods for monitoring efficacy of therapy; and apparatus for use in such methods. | 01-27-2011 |
20110020471 | ERYTHROCYTE ATP-RELEASE MODULATORS - Erythrocyte ATP-release modulators and composition and methods for their use to potentiate serum glucose clearance and vasodilation; methods for prophylactic or palliative therapy of glucose processing or vascular disorders; processes for preparing the modulators and compositions comprising them; and kits therefor. | 01-27-2011 |
20110003897 | METHODS OF ENGINEERING POLAR DRUG PARTICLES WITH SURFACE-TRAPPED HYDROFLUOROALKANE-PHILES - Disclosed herein are polar drug particles with surface-trapped hydrofluoroalkane-philes and methods of making the same. | 01-06-2011 |
20110002930 | Activated T Cells - Provided are compositions comprising activated T cells and activated T cells armed with bispecific antibodies directed at cancer antigens which are poor responders to alloantigen, and methods of using the compositions to help engraftment and improve anti-tumor effects. | 01-06-2011 |
20100322871 | Co-polymer Stabilizers For Hydryfluoroalkane Dispersions - The use of biodegradable and biocompatible lactide-based nonionic amphiphiles to stabilize a model drug (salbutamol base) dispersion in hydrofluoroalkane (HFA) propellant is disclosed. The results have industrial applicability to the development of HFA-based dispersion pressurized metered-dose inhaler formulations. | 12-23-2010 |
20100280091 | TRI-SUBSTITUTED 2-BENZHYDRYL-5-BENZYLAMINO-TETRAHYDRO-PYRAN-4-OL AND 6-BENZHYDRYL-4-BENZYLAMINO-TETRAHYDRO-PYRAN-3-OL ANALOGUES, AND NOVEL 3,6-DISBUSTITUTED PYRAN DERIVATIVES - Novel 3,6-disubstituted pyrans, optionally with a further substituent at the 4-position, are monoamine reuptake inhibitors with activity profiles of anti-depressants. | 11-04-2010 |
20100273745 | POLYAMINES USEFUL AS ANTI-PARASITIC AND ANTI-CANCER THERAPEUTICS AND AS LYSINE-SPECIFIC DEMETHYLASE INHIBITORS - Polyamine, polyamine/guanidino, and polyamine/biguanide compounds are disclosed. The compounds are useful as anti-cancer and anti-parasitic treatments. The compounds are also useful as inhibitors of the enzyme lysine-specific demethylase-1. | 10-28-2010 |
20100239765 | COMPOUNDS FOR FORMING METAL NITRIDES - Nitride forming precursors are heated to form a metal nitride on a substrate. In some variations, the precursors are contacted with the substrate which has previously been heated to a sufficient temperature to form a nitride film. Precursors to tungsten and molybdenum nitride are provided. | 09-23-2010 |
20100233700 | UBIAD1 GENE AND HYPERLIPIDEMIA - The disclosure relates to genetic mutations in UBIAD1 gene that segregate with Schnyder's crystalline corneal dystrophy. The disclosure provides methods for detecting such mutations as a diagnostic for Schnyder's crystalline corneal dystrophy either before or after the onset of clinical symptoms. Also provided are screening methods for identifying medical conditions related to cholesterol metabolism, including atherosclerosis, risk of future loss of vision, and future need for corneal transplantation. | 09-16-2010 |
20100210663 | Hybrid 2-Aminotetralin and Aryl-Substituted Piperazine Compounds and their Use in Altering CNS Activity - Hybrid compounds containing an aminotetralin moiety or a heterocyclic and/or open chain analog thereof linked through an alkylene group to an aryl ring system-substituted piperidiene moiety exhibit high levels of CNS activity, in some cases exhibiting especially high relative binding efficiencies between D3 and D2 dopaminergic receptor subtypes. | 08-19-2010 |
20100202969 | NANOPARTICLES FOR IMAGING AND TREATING CHLAMYDIAL INFECTION - Compositions of nanoparticles and targeting moieties for imaging and treating Chlamydial infection are provided, including nanoparticles conjugated to folic acid and comprising at least one antibiotic effective against | 08-12-2010 |
20100183875 | PARTICLE-ROD NANOSTRUCTURES - A particle-rod nanostructure is disclosed. The nanostructure comprises an inorganic nanoparticle coated with a capping agent and an organic crystalline rod nucleated on the capped inorganic nanoparticle in a one-dimensional growth pattern. | 07-22-2010 |
20100104516 | USE OF FLAGELLIN TO PREVENT AND TREAT GRAM NEGATIVE BACTERIAL INFECTION - The disclosure describes use of flagellin polypeptides to induce tolerance to gram negative bacteria, such as | 04-29-2010 |
20100098679 | PROMOTION OF PEROXISOMAL CATALASE FUNCTION IN CELLS - The molecular mechanisms of peroxisome biogenesis have begun to emerge; in contrast, relatively little is known about how the organelle functions as cells age. The present inventors characterized age-related changes in peroxisomes of human cells and showed that aging compromises peroxisomal targeting signal 1 (PTS1) protein import, with the critical antioxidant enzyme, catalase, especially affected. The number and appearance of peroxisomes are altered in these cells, and the organelles accumulate the PTS1-import receptor, Pex5p, on their membranes. Concomitantly, cells produce increasing amounts of the toxic metabolite, H | 04-22-2010 |
20100043881 | TITANIUM DIOXIDE THIN FILM SYSTEMS AND METHOD OF MAKING SAME - A method for producing a thin film titanium dioxide is disclosed. The disclosed method for producing the thin film titanium dioxide includes performing a magnetron reactive sputtering process to vaporize at least portions of a titanium source in a sputtering chamber that is supplied with gaseous oxygen. The vaporized titanium reacts with the oxygen to form anatase titanium dioxide, which is deposited on a substrate within the sputtering chamber. | 02-25-2010 |
20100037682 | BIOSENSOR BASED ON POLYMER CANTILEVERS - A microcantilever sensor includes a supporting substrate, a cantilever spring element at least partially disposed over the support substrate, a probe layer disposed over the first side of the cantilever spring element, and a piezoresistive transducer attached to the second side of the cantilever spring element. The cantilever spring element is characterized by having a first side and a second side and comprising a polymer having a Young's modulus less than about 100 Gpa. Sensing systems that incorporate the cantilever sensor of the invention include a detector in communication with the piezoresistive transducer to provide measurements of surface strain changes in the piezoresistive transducer. | 02-18-2010 |
20100028977 | ENCLOSED PHOTOBIOREACTORS WITH ADAPTIVE INTERNAL ILLUMINATION FOR THE CULTIVATION OF ALGAE - The present invention provides an enclosed, internally-lighted bioreactor apparatus, methods for growing photosynthetic microorganisms in the enclosed, internally lighted bioreactor and methods for enhancing growth of a photosynthetic microorganism culture in the enclosed internally-lighted bioreactor. | 02-04-2010 |
20100016600 | N- and O-Substituted 4-[2-(Diphenylmethoxy)-Ethyl]-1-[(Phenyl)Methyl]Piperdine Analogs and Methods of Treating CNS Disorders Therewith - N- and O-substituted 4[2-diaromaticmethoxy and methylamino)alkyl]piperidines exhibit high CNS activity with respect to the dopamine transporter (DAT) and serotonin transporter (SERT). Preferred compounds exhibit highly differential behavior as between the DAT and SERT and between the DAT and the norepinephrine transporter (NET). The compounds have utility in treating CNS disorders, including but not limited to cocaine addiction, depression, and Parkinson's disease. | 01-21-2010 |
20100015095 | RESTORATION OF VISUAL RESPONSES BY IN VIVO DELIVERY OF RHODOPSIN NUCLEIC ACIDS - Nucleic acid vectors encoding light-gated cation-selective membrane channels, in particular channelrhodopsin-2 (Chop2), converted inner retinal neurons to photosensitive cells in photoreceptor-degenerated retina in an animal model. Such treatment restored visual perception and various aspects of vision. A method of restoring light sensitivity to a retina of a subject suffering from vision loss due to photoreceptor degeneration, as in retinitis pigmentosa or macular degeneration, is provided. The method comprises delivering to the subject by intravitreal or subretinal injection, the above nucleic acid vector which comprises an open reading frame encoding a rhodopsin, to which is operatively linked a promoter and transcriptional regulatory sequences, so that the nucleic acid is expressed in inner retinal neurons. These cells, normally light-insensitive, are converted to a light-sensitive state and transmit visual information to the brain, compensating for the loss, and leading to restoration of various visual capabilities. | 01-21-2010 |
20100015050 | PEG AND TARGETING LIGANDS ON NANOPARTICLE SURFACE - Provided are compositions of nanoparticles, PEG and targeting moieties. The compositions are useful in treating tumors, imaging the particles in tissues, and in targeting therapeutic agents to specific tissues and locations in a patient. Also provided are methods of preparing and methods of using the compositions. | 01-21-2010 |
20090311721 | ASBESTOS EXPOSURE, PLEURAL MESOTHELIOMA, AND SERUM OSTEOPONTIN LEVELS - The present invention provides diagnostic methods based on the serum levels of osteopontin. | 12-17-2009 |
20090298111 | METHOD AND COMPOSITION FOR A PROTEIN TRANSDUCTION TECHNOLOGY AND ITS APPLICATIONS - A protein transduction method for efficiently delivery of exogenous proteins into mammalian cells is invented, which has the capability of targeting different cellular compartments and protection from degradation of the delivered proteins from cellular proteases. A composition for treat proteins has cation reagents, lipids and enhancers in a carrier. The method can be used in a number of ways including: production of large quantities of properly folded, post-translationally modified proteins using mammalian cell machinery, a in-cell fluorescence spectroscopy and imaging using small molecule fluorophores and a in-cell NMR spectroscopy using living mammalian cells. The method permits cell biology at atomic resolution that is physiologically and pathological relevant and permits protein therapy to treat human diseases. The method can also be used to deliver exogenous protein inside mammalian cells, wherein the exogenous proteins follow a similar secretion pathway as that of the endogenous protein. | 12-03-2009 |
20090269779 | Galectin-3 cleavage as a marker for matrix metalloproteinase activity in cancer - Provided are differential antibodies recognizing the cleaved and non-cleaved forms of matrix metalloproteinases (MMPs), and methods of using the antibodies as surrogate diagnostic markers for the presence of active MMPs in cancer, such as growing breast cancers. | 10-29-2009 |
20090232648 | REDUCTION OF FLOW-INDUCED NOISE IN A CENTRIFUGAL BLOWER - A centrifugal blowing apparatus for reducing flow-induced noise is disclosed. The apparatus includes a blower housing having a scroll section formed about a rotational axis and an exhaust section extending from the scroll section. The scroll section includes an opening defining an inlet configured to draw in air and the exhaust section defines an outlet in fluid communication with the inlet. The scroll section commences with a reduced cross-sectional area defining a cutoff and expands to an increased cross-sectional area. An impeller is disposed in the opening of the scroll section about the rotational axis and comprises an outer surface having impeller blades radially disposed thereon. The impeller blades rotate to direct a flow of air from the inlet through the scroll section to the outlet. A plurality of indentations is formed along an inner surface of the scroll section at the cutoff. | 09-17-2009 |
20090214590 | Virus Vaccines Comprising Envelope-Bound Immunomodulatory Proteins and Methods of Use Thereof - The present invention provides novel virus vaccines with augmented, e.g., enhanced and/or extended immunogenicity. The virus vaccines of the invention comprise an envelope-bound immunomodulatory protein, e.g., a cytokine, chemokine or costimulatory molecule. The immunomodulatory protein serves as an adjuvant to augment, e.g., enhance or extend the immunogenicity of the virus vaccine, thereby augmenting, e.g., enhancing or extending immune response to the virus when administered to a subject. | 08-27-2009 |
20090188576 | CHECK VALVE DIAPHRAGM MICROPUMP - A micropump device including a first wafer and a second wafer attached to the first wafer. The first and second wafers are configured to define a chamber therebetween having a predetermined volume. A third wafer is attached to the second wafer to define an inlet section and an outlet section in fluid communication with the chamber. At least one of the second and third wafers are formed to define a moveable diaphragm configured to change the predetermined volume of the chamber for pumping a fluid between the inlet section and the outlet section. | 07-30-2009 |
20090182019 | Histone deacetylase inhibitors - The present invention provides novel HDAC inhibitors and methods of treating diseases using the same. | 07-16-2009 |
20090173700 | DEVICE AND METHOD OF SEPARATING AND CONCENTRATING MICROFLUIDIC PARTICLES - A flow unit for microfluidic particles separation and concentration is disclosed. The unit comprises a nozzle segment, a turn segment, and a diffuser segment. The nozzle segment is defined by a first member and a second member, and has an opening through which fluid and microfluidic particles enter. The nozzle segment has a narrowing portion at which the first and second members narrow from the opening to increase momentum of the fluid therethrough. The turn segment is defined by the first member flaring outwardly downstream from the narrowing portion to change flow direction of the fluid consistent with the first member. The diffuser segment is defined by the second member extending past the turn segment to facilitate separation of the microfluidic particles from the fluid due to the inability to follow the fluid flow. | 07-09-2009 |
20090142936 | METHOD OF FORMING GATED, SELF-ALIGNED MICRO-STRUCTURES AND NANO-STRUCTURES - Methods of forming a gated, self-aligned nano-structures for electron extraction are disclosed. One method of forming the nano-structure comprises irradiating a first surface of a thermally conductive laminate to melt an area across the first surface of the laminate. The laminate comprises a thermally conductive film and a patterned layer disposed on the first surface of the film. The patterned layer has a pattern formed therethrough, defining the area for melting. The film is insulated at a second surface thereof to provide two-dimensional heat transfer laterally in plane of the film. The liquid density of the film is greater than the solid density thereof. The method further comprises cooling the area inwardly from the periphery thereof to form the nano-structure having an apical nano-tip for electron emission centered in an electrically isolated aperture that serves as a gate electrode to control electron extraction in a gated field emitter device. | 06-04-2009 |
20090118308 | 2,2-Bis-(hydroxymethyl)cyclopropylidenemethyl-Purines and -Pyrimidines As Antiviral Agents - Compounds which are active against viruses have the following formulas: | 05-07-2009 |
20090035310 | CANCER TREATMENT - Pharmaceutical compositions and methods for inhibiting tumor growth and/or for inducing apoptosis are provided. Such compositions comprise at least one polypeptide of contiguous amino acids 1-198, 197-454, or 896-1150 of CARP-1 protein, and derivatives thereof, and may optionally comprise one or more cancer chemotherapeutic agents. Also provided are plasmids encoding the polypeptides, and methods of using the polypeptides and plasmids to inhibit cancer cell growth, including in mammals. | 02-05-2009 |
20080227707 | BIOACTIVE PEPTIDES AND UNIQUE IRES ELEMENTS FROM MYELIN PROTEOLIPID PROTEIN PLP/DM20 - Three novel low molecular weight (LMW) polypeptide fragments of a proteolipid protein human PLP/DM20 are designated PIRP-M, PIRP-L and PIRP-J, and are growth factors for oligodendrocytes with anti-apoptotic activity. They are encoded by mRNA from an IRES. Fusion polypeptides of such a LMW polypeptide, DNA encoding the LMW polypeptide and fusion polypeptide, expression vectors comprising such DNA, and cells expressing such polypeptides, or pharmaceutical compositions thereof, are useful for stimulating neural stem cell differentiation, maturation along the oligodendrocytic pathway and proliferation of oligodendrocytes or precursors. These compositions can protect oligodendrocytes (and nonneural cells) from apoptotic death. Thus, the present composition is used to treat a disease or condition in which such differentiation, maturation and proliferation or inhibition of cell death, including remyelination or stimulation of oligodendroglia or Schwann cells, is desirable. Disorders include multiple sclerosis, trauma with Parkinson's-like symptoms, hypoxic ischerriia and spinal cord trauma. | 09-18-2008 |
20080199659 | TRANSPARENT HYDROPHOBIC ARTICLE HAVING SELF-CLEANING AND LIQUID REPELLANT FEATURES AND METHOD OF FABRICATING SAME - A transparent hydrophobic article having self-cleaning and liquid repellent features is disclosed. The article comprises a transparent substrate comprising a subwavelength structured surface including arrays of protuberances. Each protuberance has a predetermined distance to its adjacent neighbor and a predetermined height to minimize light diffraction and random scattering therethrough. The article further comprises a hydrophobic material disposed on the subwavelength structured surface. The hydrophobic material has a predetermined thickness and a predetermined hydrophobicity for self-cleaning and repelling from fluids thereon. | 08-21-2008 |